Anthera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 25   

Articles published

ANTH 1.88 -0.01 (-0.53%)
price chart
PowerSecure International Inc. (POWR), Anthera Pharmaceuticals Inc (ANTH ...
Last Friday, Kevin Kotler's Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH). According to a Schedule 13G filed with the Securities and Exchange Commission, the fund now owns ...
Top News : International Business Machines Corporation (NYSE:IBM), Anthera ...
Anthera Pharmaceuticals Inc (NASDAQ:ANTH), whose shares are down more than 41% this year, said it was in talks that could lead to an important partnership arrangement regarding blisibimod, its product in the pipeline.
Anthera Pharmaceuticals Announces Update on Strategic Partnership ...
HAYWARD, Calif., Oct. 1, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
Related articles »  
Anthera Pharmaceuticals Downgraded by Zacks to Neutral (ANTH)
Anthera Pharmaceuticals Inc logo Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by Zacks from an �outperform� rating to a �neutral� rating in a research report issued on Tuesday.
Related articles »  
Anthera Pharmaceuticals Stock Rating Lowered by Zacks (ANTH)
Anthera Pharmaceuticals Inc logo Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by Zacks from an �outperform� rating to a �neutral� rating in a research note issued to investors on Tuesday.
Related articles »  
Hot Stock List : Hewlett-Packard Company (NYSE:HPQ), JPMorgan Chase & Co ...
On Oct. 1, Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
News Buzz: Merck & Co. Inc. (NYSE:MRK), Staples, Inc. (NASDAQ:SPLS ...
Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.15.
Immunomedics Inc. (IMMU) Jumps: Stock Up 6.6% in Session
Some better-ranked stocks worth considering in the technology sector include Cambrex Corporation. (CBM - Snapshot Report), Gilead Sciences Inc. (GILD - Analyst Report) and Anthera Pharmaceuticals, Inc. (ANTH). All these stocks sport a Zacks Rank #1 ...
Genomic Health Upbeat on Strong International Performance
Some other well-placed stocks from the Med-Biomed/Generic industry include Anthera Pharmaceuticals, Inc. (ANTH - Snapshot Report), Cambrex Corporation.
Genomic Health Upbeat on Strong International Performance - Analyst Blog
The company reported better-than-expected second-quarter 2014 results with both the top and the bottom line surpassing the respective Zacks Consensus Estimate.